Abstract
Human papillomaviruses (HPVs) are a group of host-specific DNA viruses, with more than 120 different types identified to date. HPVs are classified as high- or low-risk (HR or LR) depending on their potential to induce cancer. Persistent infections with HR types of HPVs present a major risk factor for the development of a variety of human cancers including cervical, colorectal, head and neck as well as breast cancers. On the other hand, the deregulation of ErbB family tyrosine kinase receptors has also been associated with several types of human cancers. For instance, ErbB2 has been shown to have an important role in human carcinomas, specifically breast cancer. Moreover, the E-cadherin/catenin complex plays a pivotal role in the maintenance of normal adhesion in epithelial cells, and has been demonstrated to suppress tumor invasion and participate in cell signaling in human carcinomas. This review focuses on the interaction between HRHPV/ ErbB2 tyrosine receptors and the E-cadherin/catenin complex in human carcinomas including cervical, colorectal, head and neck and breast cancers.
Keywords: HPV, ErbB receptors, E-cadherin/catenin complex, cervical cancer, colorectal cancer, head and neck cancer and breast cancer
Current Pharmaceutical Design
Title: High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Volume: 14 Issue: 22
Author(s): Ala-Eddin Al Moustafa, Amal Kassab, Andrew Darnel and Amber Yasmeen
Affiliation:
Keywords: HPV, ErbB receptors, E-cadherin/catenin complex, cervical cancer, colorectal cancer, head and neck cancer and breast cancer
Abstract: Human papillomaviruses (HPVs) are a group of host-specific DNA viruses, with more than 120 different types identified to date. HPVs are classified as high- or low-risk (HR or LR) depending on their potential to induce cancer. Persistent infections with HR types of HPVs present a major risk factor for the development of a variety of human cancers including cervical, colorectal, head and neck as well as breast cancers. On the other hand, the deregulation of ErbB family tyrosine kinase receptors has also been associated with several types of human cancers. For instance, ErbB2 has been shown to have an important role in human carcinomas, specifically breast cancer. Moreover, the E-cadherin/catenin complex plays a pivotal role in the maintenance of normal adhesion in epithelial cells, and has been demonstrated to suppress tumor invasion and participate in cell signaling in human carcinomas. This review focuses on the interaction between HRHPV/ ErbB2 tyrosine receptors and the E-cadherin/catenin complex in human carcinomas including cervical, colorectal, head and neck and breast cancers.
Export Options
About this article
Cite this article as:
Al Moustafa Ala-Eddin, Kassab Amal, Darnel Andrew and Yasmeen Amber, High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis, Current Pharmaceutical Design 2008; 14 (22) . https://dx.doi.org/10.2174/138161208785740216
DOI https://dx.doi.org/10.2174/138161208785740216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry Role of Gut Microbiota in Human Health and Diseases
Current Nutrition & Food Science The Passive Targeting and the Cytotoxicity of Intravenous 10-HCPT Nanosuspension
Current Nanoscience Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Design, In Silico Modelling, and Functionality Theory of Novel Folate Receptor Targeted Rutin Encapsulated Folic Acid Conjugated Keratin Nanoparticles for Effective Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?
Reviews on Recent Clinical Trials The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Gold Nanostructure: Fabrication, Surface Modification, Targeting Imaging, and Enhanced Radiotherapy
Current Nanoscience Synthesis, Cytotoxicity and Antioxidant Activity of New Analogs of RC-121 Synthetic Derivatives of Somatostatin
Anti-Cancer Agents in Medicinal Chemistry Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions
Current Cancer Drug Targets